skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Emerging role of sertindole in the management of schizophrenia

Review

(1766) Views  (583) Full article downloads

Authors: Stephanie L Cincotta, Joshua S Rodefer

Published Date July 2010 Volume 2010:6(1) Pages 429 - 441
DOI: http://dx.doi.org/10.2147/NDT.S7602

Stephanie L Cincotta1, Joshua S Rodefer2

1Georgetown University School of Medicine, Washington DC, USA; 2Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, Florida, USA

Abstract: The atypical antipsychotic sertindole is a phenylindole-derived compound that has affinity for and functions as an antagonist at a number of receptor systems, including dopamine D2 receptors, 5-HT2A and 5-HT2C receptors, and a-1-noradrenergic receptors. Although previous data suggested that sertindole was well tolerated and had good efficacy against both positive and negative symptom clusters, reports of QT prolongation with sertindole prompted its voluntary removal from the market in 1998. After further safety analyses, it recently regained approval and was reintroduced to the European market for the treatment of schizophrenia, where its role in therapy among available atypicals remains unclear. This article evaluates the preclinical and clinical data regarding sertindole’s effectiveness and concludes that sertindole continues to demonstrate a number of strengths, including effective management of both positive and negative symptoms, well-tolerated side effects (including little or no sedation, weight gain, and extrapyramidal side effects), and a superior procognitive profile that is unique among atypical antipsychotics. However, minor concerns regarding its sexual side effects and the major consideration of QT prolongation suggest that additional comparative effectiveness studies are needed to determine the superiority of sertindole vs other atypical antipsychotics recently introduced.

Keywords: atypical, antipsychotic, cognition, psychosis, 5-HT2, 5-HT6






Readers of this article also read:

The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease
Optimal management of Alzheimer’s disease patients: Clinical guidelines and family advice
Long-acting injectable antipsychotics: focus on olanzapine pamoate
Overview of essential tremor
Fitting the pieces together: current research on the genetic basis of attention-deficit/hyperactivity disorder (ADHD)
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Depression care and prevalence in HIV-positive individuals
The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
Testing the generalizability of national reimbursement rates with respect to local setting: the costs of abdominal aortic aneurysm surgery in Denmark
Effect of HIV infection on time to recovery from an acute manic episode